Filtered By:
Cancer: Leukemia

This page shows you your search results in order of relevance. This is page number 9.

Order by Relevance | Date

Total 266 results found since Jan 2013.

Atrial fibrillation in CLL patients treated with ibrutinib. An international retrospective study
Summary Atrial fibrillation (AF) occurs in 5–9% of patients treated with ibrutinib for chronic lymphocytic leukaemia (CLL); the clinical consequences and optimal management are unclear. We retrospectively studied 56 CLL patients who received ibrutinib and developed AF. Median time to onset was 3·8 months. AF was persistent in 35/56 (62%) cases despite treatment. Clinical consequences included: three episodes of severe cardiac failure (one fatal) and one stroke; eight non‐thrombocytopenic patients (14%) experienced severe bleeding adverse events. Altogether, ibrutinib was permanently discontinued in 26/56 cases (46%)....
Source: British Journal of Haematology - September 8, 2016 Category: Hematology Authors: Philip A. Thompson, Vincent L évy, Constantine S. Tam, Chadi Al Nawakil, François‐Xavier Goudot, Anne Quinquenel, Loic Ysebaert, Anne‐Sophie Michallet, Marie‐Sarah Dilhuydy, Eric Van Den Neste, Jehan Dupuis, Michael J. Keating, Christophe Meune, F Tags: Short Report Source Type: research

Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era
Conclusions:The current era of retinoblastoma management using intra-arterial chemotherapy plus additional intravitreal chemotherapy (as needed for vitreous seeding) has improved globe salvage in eyes with advanced retinoblastoma.[J Pediatr Ophthamol Strabismus. 201X;XX(X):XX –XX.]
Source: Journal of Pediatric Ophthalmology and Strabismus - September 19, 2016 Category: Opthalmology Source Type: research

Men From The South Are More Likely To Die From Smoking-Related Cancers
Smoking causes nearly 29 percent of all cancer deaths among Americans over the age of 35, according to a new analysis published in JAMA Internal Medicine. But that doesn’t tell the full story. Men from the top five southern states skew this data, dying at a rate that’s 40 percent higher than the national average. The higher proportion of cancer deaths attributable to smoking in the South isn’t simply because people in that region smoke more ― that distinction goes to the Midwest. Instead, experts say, the lack of funding for tobacco control programs means that there are less resources for people wh...
Source: Science - The Huffington Post - November 1, 2016 Category: Science Source Type: news

Stroke-like encephalopathy following high-dose intravenous methotrexate in an adolescent with osteosarcoma: a case report
ABSTRACT Chronic lymphocytic leukemia is characterized by clonal proliferation and progressive accumulation of B-cell lymphocytes that typically express CD19+, CD5+ and CD23+. The lymphocytes usually infiltrate the bone marrow, peripheral blood, lymph nodes, and spleen. The diagnosis is established by immunophenotyping circulating B-lymphocytes, and prognosis is defined by two staging systems (Rai and Binet) established by physical examination and blood counts, as well as by several biological and genetic markers. In this update, we present the recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia for th...
Source: Revista Brasileira de Hematologia e Hemoterapia - December 29, 2016 Category: Hematology Source Type: research

Reflections on the Future of Medicine
Recently, I traveled through China. I climbed mountains, hiked through forests, crossed deep valleys. I visited cities of every size. I floated across lakes and traveled beautiful shorelines churning with life. As a man of a certain age, I began to compare the permanence of the timeless landscape with the evanescence of my own existence. Yet, as a scientist, I knew these reflections were flawed. Scientists are trained to think in terms of aeons, millenia, and lifetimes. Consider the paradox. Is it the solid mountain or fragile the forest that is permanent? Is it the massive shoreline cliffs or the teeming shore life that...
Source: Science - The Huffington Post - January 9, 2017 Category: Science Source Type: news

Stability and change in disease prestige: A comparative analysis of three surveys spanning a quarter of a century
Publication date: Available online 14 March 2017 Source:Social Science & Medicine Author(s): Dag Album, Lars E.F. Johannessen, Erik B. Rasmussen In this paper, we present a comparative analysis of three survey studies of disease prestige in medical culture. The studies were conducted in 1990, 2002 and 2014 using the same research design. In each of the three rounds, a sample of Norwegian physicians was asked to rate a set of 38 diseases on a scale from 1 to 9 according to the prestige they believed health personnel in general would award them. The results show a remarkable stability in the prestige rank order over...
Source: Social Science and Medicine - March 14, 2017 Category: Psychiatry & Psychology Source Type: research

Cardiovascular Complications of Targeted Therapies for Chronic Myeloid Leukemia
Opinion statementThe development of tyrosine kinase inhibitors (TKIs) dramatically changed the treatment landscape for many different cancers including chronic myeloid leukemia (CML). With the introduction of imatinib, the first TKI developed and approved to effectively treat CML, patient survival has increased dramatically and, in some cases, this fatal cancer can be managed as a chronic disease. Since the approval of imatinib in 2002, four additional TKIs have been developed to treat this disease including the second-generation TKIs nilotinib, dasatinib, and bosutinib and the third-generation TKI ponatinib. Despite their...
Source: Current Treatment Options in Cardiovascular Medicine - March 17, 2017 Category: Cardiology Source Type: research

Mangosteen: The Cancer-Fighting Superfruit
  If you're a woman with a family history of breast cancer, your doctor may recommend you start taking a toxic chemo drug like tamoxifen to lower your risk of developing the disease. Even if you have no signs or symptoms of cancer. Tamoxifen is what's known as a chemopreventive agent. That's a fancy phrase that means it's something that prevents cancer from forming. But its track record isn't all that impressive. Trials found that for every 1,000 women who take the drugs, only 21 to 35 cases of cancer would be prevented. And the side effects are downright terrifying. Bone pain, blood clots, increas...
Source: Al Sears, MD Natural Remedies - March 23, 2017 Category: Complementary Medicine Authors: Cathy Card Tags: Anti-Aging Source Type: news

Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials.
Abstract We analyzed adverse events (AEs) in 201 chronic phase CML patients treated with nilotinib (n = 120) or dasatinib (n = 81) as first- or second-line therapy. The dasatinib group had significantly higher grade 3-4 AEs compared to the nilotinib group (22 vs. 54%, p < 0.001), and had more frequent dose reduction, interruption, and discontinuation (p < 0.001, p = 0.004, and p = 0.006, respectively). Of 59 patients who discontinued treatment, 47 (80%) discontinued treatment due to AEs; 50% of the AEs causing drug discontinuation were of grade 2 severity. Compared to the second-line setting, dis...
Source: International Journal of Hematology - April 4, 2017 Category: Hematology Authors: Suh KJ, Lee JY, Shin DY, Koh Y, Bang SM, Yoon SS, Park S, Kim I, Lee JO Tags: Int J Hematol Source Type: research

Intracranial stenting for nilotinib treatment-associated cerebrovascular stenosis in chronic myeloid leukemia.
Authors: Ozaki T, Nakamura H, Izutsu N, Masaie H, Ishikawa J, Kinoshita M Abstract One of the second-generation tyrosine kinase inhibitors (TKIs), nilotinib, is increasingly used for imatinib-resistant or intolerant chronic myeloid leukemia (CML). Nilotinib is considered well tolerated with few side effects including hyperglycemia, hyperbilirubinemia and elevated levels of pancreatic enzymes. However, there is growing evidence that nilotinib accelerates atherosclerosis and causes peripheral arterial occlusive disease such as stroke, transient ischemic attack (TIA) and cardiovascular diseases. Herein, we report a ca...
Source: Interventional Neuroradiology - June 8, 2017 Category: Radiology Tags: Interv Neuroradiol Source Type: research

Elevated Cardiovascular Disease Risk in Patients With Chronic Myelogenous Leukemia Seen in Community-based Oncology Practices in the United States
Conclusion The increased risk of CVD observed in this real-world analysis of CML patients underscores the importance of current NCCN® recommendations to consider CV risk when selecting TKIs. Teaser Guidelines recommend that comorbidities, including CVD, be considered when selecting TKIs for the treatment of CML. An increased risk of CVD and its risk factors in CML patients treated by community-based US oncologists was identified in a real-world analysis of an EMR database (N=1,639). These results underscore the importance of current NCCN® recommendations to consider CV risk when selecting TKIs.
Source: Clinical Lymphoma Myeloma and Leukemia - June 20, 2017 Category: Cancer & Oncology Source Type: research

Luteolin: How To Reduce Breast Cancer Risk
More than 100 women die of breast cancer in the U.S. every day. It's the second leading cause of cancer deaths in American women. But in my opinion, many of those women really die of a tragic medical error. Let me explain… Millions of women in the U.S. have taken Big Pharma's hormone replacement therapy (HRT). Their doctors prescribe it to try to relieve the symptoms of menopause. Like hot flashes, night sweats, mood swings and weight gain. But what the drug companies try to pass off as hormones are actually synthetic concoctions. They are fake versions of the estrogen and progesterone that your body makes n...
Source: Al Sears, MD Natural Remedies - June 23, 2017 Category: Complementary Medicine Authors: Al Sears Tags: Anti-Aging Source Type: news

KCa3.1 Channel Modulators as Potential Therapeutic Compounds for Glioblastoma.
This article will briefly review the available compounds (TRAM-34, senicapoc, NS6180), their binding sites and mechanisms of action, and then discuss the potential usefulness of these compounds for the treatment of brain tumors based on their brain penetration and their efficacy in reducing microglia activation in animal models of ischemic stroke and Alzheimer's disease. Senicapoc, which has previously been in Phase III clinical trials, would be available for repurposing, and could be used to quickly translate findings made with other KCa3.1 blocking tool compounds into clinical trials. PMID: 28676010 [PubMed - as supplied by publisher]
Source: Current Neuropharmacology - June 30, 2017 Category: Drugs & Pharmacology Authors: Brown BM, Pressley B, Wulff H Tags: Curr Neuropharmacol Source Type: research